Genmab A/S
CSE:GMAB
Genmab A/S
Total Current Assets
Genmab A/S
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Total Current Assets
kr27.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
15%
|
CAGR 10-Years
26%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Current Assets
kr8.5B
|
CAGR 3-Years
70%
|
CAGR 5-Years
43%
|
CAGR 10-Years
31%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Current Assets
€1.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
35%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Current Assets
kr5.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
55%
|
CAGR 10-Years
16%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Current Assets
kr83.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
19%
|
CAGR 10-Years
9%
|
|
|
Saniona AB
STO:SANION
|
Total Current Assets
kr324.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
44%
|
CAGR 10-Years
38%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Total Current Assets?
Total Current Assets
27.9B
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Total Current Assets amounts to 27.9B DKK.
What is Genmab A/S's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
26%
Over the last year, the Total Current Assets growth was -16%. The average annual Total Current Assets growth rates for Genmab A/S have been 7% over the past three years , 15% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet